medigraphic.com
ISSN 2221-2434 (Electronic)

2014, Number 4

<< Back Next >>

Finlay 2014; 4 (4)

Cardiovascular risks factors and their relationship with disorders of carbohydrate and lipid metabolism

Leguen GL, Castellanos M, Sánchez BMJ, Benet RM

Language: Spanish
References: 17
Page: 248-260
PDF size: 188. Kb.


ABSTRACT

Background: cardiovascular disease has been the leading cause of death in Cuba, where studies on emerging cardiovascular risk factors as predictors of cardiovascular risk are scarce.
Objective: to determine the association between cardiovascular risk factors and disorders of carbohydrate and lipid metabolism.
Methods: a correlational study was conducted with a sample of 105 men and women selected from a total of 346 workers of the University of Medical Sciences of Cienfuegos from June 2011 through July 2012. The variables analyzed were age, sex, blood pressure, waist circumference, tobacco use, fasting blood glucose, triglycerides, cholesterol, HDL cholesterol, apolipoprotein A and B, TC/HDL ratio and apo B/apo AI ratio.
Results: women older than 45 years had a higher prevalence of elevated waist circumference (60.0 %), hypertension (46.7 %) and type 2 diabetes mellitus (54.3 %) with hypertriglyceridemia (43.3 %), low HDLc levels (36.7 %) and were 2.8 times more likely to develop elevated waist circumference; 66.7 % of the diabetic patients had low HDLc levels, 33.3 % developed hypertriglyceridemia and 66.7 % had a high total cholesterol/HDL cholesterol ratio.
Conclusions: an association between age older than 45 years, female sex, obesity, hypertension and type 2 diabetes mellitus was observed. There was a higher prevalence of hypertriglyceridemia and low HDL cholesterol levels in obese and diabetic patients. Increased risk of low HDL cholesterol and high total cholesterol / HDL cholesterol ratio were also found.


REFERENCES

  1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001 ; 285 (19): 2486-97.

  2. Benet M, Morejón AF, Espinosa AD, Landrove O, Peraza D, Ordúñez PO. Factores de Riesgo para Enfermedades Crónicas en Cienfuegos, Cuba 2010. Resultados preliminares de CARMEN II. Medisur [revista en Internet]. 2010 ; 8 (2): [aprox. 4p]. Available from: http://www.medisur.sld.cu/index.php/medisur/arti cle/view/1166/70.

  3. Chobanian A, Bakris G, Black H, Cushman W, Green L, Izzo J, et al. Séptimo Informe del Comité Nacional Conjunto en Prevención, Detección Evaluación y Tratamiento de la Hipertensión Arterial. Hipertensión. 2003 ; 42 (1): 1206-52.

  4. Millán J, Pintó X, Muñoz A, Zúñiga M, Rubiés J, Pallardo LF, et al. Cocientes lipoproteicos: significado fisiológico y utilidad clínica de los índices aterogénicos en prevención cardiovascular. Clin Invest Arterioscl. 2010 ; 22 (1): 25-32.

  5. Ryan AS, Nicklas BJ. Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. Diabetes Care. 2004 ; 27 (7): 1699-705.

  6. Pasquali R, Vicennati V. Activity of the hypothalamic-pituitary-adrenal axis in different obesity phenotypes. Int J Obes Relat Metab Disord. 2000 ; 24 Suppl 2: SS47-9.

  7. Hernández M, Miguel PE, Marrero MM, Pérez LM, Peña I, Rivas M. Comportamiento de variables clínicas, antropométricas y de laboratorio en pacientes con síndrome metabólico. Medisur [revista en Internet]. 2011 ; 9 (2): [aprox. 8p]. Available from: http://www.medisur.sld.cu/index.php/medisur/arti cle/view/1260/716.

  8. Bello BM, Sánchez G, Campos A, Báez EG, Fernández J, Achiong J. Definiciones del síndrome metabólico. Rev Med Electrón. 2013 ; 35 (2): 215-7.

  9. Ruano M, Silvestre V, Aguirregoicoa E, Criado L, Duque Y, García G. Nutrición, síndrome metabólico y obesidad mórbida. Nutr Hosp (Madrid). 2011 ; 26 (4): 759-64.

  10. Londoño ME. Tratamiento farmacológico contra la obesidad. Rev Col Cienc Quím Farmac. 2012 ; 41 (2): 217-61.

  11. Martínez MD. Estudio de biomarcadores de inflamación y de riesgo cardiovascular en niños obesos prepúberes [Internet]. Córdoba: Servicio de Publicaciones de la Universidad de Córdoba; 2010. [ cited 12 May 2013 ] Available from: http://helvia.uco.es/xmlui/handle/10396/3661.

  12. Wormser D, Kaptoge S, Di Angelantonio E, Wood AM, Pennells L, et al; Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet. 2011 ; 377 (9771): 1085-95.

  13. Morales M, Carvajal CF. Obesidad y resistencia a la leptina. Gac Med Bol. 2010 ; 33 (1): 63-8.

  14. García D, Castellanos MF, Cedeño R, Benet M, Ramírez I. Tejido adiposo como glándula endocrina. Implicaciones fisiopatológicas. Finlay [revista en Internet]. 2011 ; 1 (2): [aprox. 21p]. Available from: http://www.revfinlay.sld.cu/index.php/finlay/articl e/view/39/1208.

  15. Modrego A, Rodríguez MP, Cucalón JM, Tarraga PJ, Robledo M, Montilla L, et al. Impacto de la prediabetes y el sexo en el riesgo cardiovascular asociado al síndrome metabólico. Hiperten riesgo vasc. 2010 ; 27 (1): 4-12.

  16. de la Fuente RA, de Luis DA, Conde R, Izaola O, de la Fuente B, González M. Relación del polimorfismo rs9939609 del gen FTO con factores de riesgo cardiovascular y niveles de adipocitoquinas en pacientes con obesidad mórbida. Nutr Hosp. 2012 ; 27 (4): 1184-9.

  17. Santos CG, Badimón JJ. Lipoproteínas de alta densidad y reducción de riesgo cardiovascular: ¿promesas o realidades?. Rev Esp Cardiol. 2012 ; 65 (4): 305-8.




2020     |     www.medigraphic.com